Search Results

Ireland built a life-science powerhouse by being the easiest place in Europe for global talent to land and stay. The proposed move from five to eight years for citizenship changes the terms on which the sector's skilled workforce agreed to come here. This analysis looks at what it means for engineers and scientists on Critical Skills permits, for the companies that depend on them, and what a fairer Bill would look like.

The 9th Annual Corporate Compliance & Transparency in Life Sciences conference runs 17-18 November 2026 in Zurich. Here is everything you need to register: dates, agenda highlights, confirmed speakers, ticket pricing, and an exclusive 20 percent discount code for Priya Life Science readers.

As the EU AI Act, updated EFPIA codes, and multi-jurisdictional enforcement reshape life sciences, the 9th Annual Corporate Compliance & Transparency in Life Sciences Conference in Zurich sets the critical 2027 benchmark for Irish biopharma leaders.

An in-depth salary and purchasing power analysis for Ireland's life sciences sector. Comparing gross €100k+ compensation packages against progressive marginal taxes, housing rent, and net disposable income in Dublin and Cork versus Basel, Munich, and Copenhagen.

An in-depth analysis of Ireland's €93.8 billion pharmaceutical and medical exports to non-EU markets. Examining trade data across the United States, UK, Switzerland, and Asia-Pacific, key manufacturing clusters in Cork, Dublin, and Limerick, and the strategic outlook for 2026.

An in-depth clinical and market analysis of GLP-1 therapeutics in 2026, examining central brain reward circuit mapping from the University of Virginia, Phase 3 oral small-molecule data for Orforglipron, Retatrutide triple-agonist efficacy, and systemic cardiometabolic benefits.

Global equity markets open August 2026 on a historic high as rumored $400B AstraZeneca-BMS merger talks and Curium's $8B Lantheus acquisition spark a massive biopharmaceutical consolidation wave.

An in-depth, fact-based analysis of water and power consumption across Ireland’s twin industrial pillars, the infrastructure bottlenecks, and the shifting geography of high-tech construction.

The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.

GEODIS has renewed its IATA CEIV Pharma accreditation in Warsaw and secured GDP certification for its Stryków Dobra contract logistics facility. This dual compliance milestone bolsters Poland’s status as a critical gateway in Europe’s pharmaceutical supply chain.

Recent reports suggest Irish pharma workers are the highest paid in Europe, but a deeper dive reveals a more complex reality. We analyze compensation packages, tax regimes, and cost of living across Europe’s top pharmaceutical hubs.

An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.

An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.

Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.

An in-depth analysis of Ireland's National Life Science Innovation Strategy in 2026. We examine the structural challenges of this transition-including specialised R&D infrastructure, the acute talent shortage in cell and gene therapies (CGT), and how digital compliance tools like Priya LifePDF streamline the transition.